K-made new anti-cancer drugs to unveil at conference
By Son, Hyung-Min | translator Kang, Shin-Kook
24.09.06 05:45:45
가나다라
0
The effectiveness of Rivoceranib has been confirmed in various solid cancers, such as liver cancer·cholangiocarcinoma·esophageal cancer
TiumBio·ABION BIO·Eutilex will unveil the results of their candidates, including immune checkpoint inhibitors and CAR-T
▲South Korea-based pharmaceutical and biotech companies will unveil their clinical results at the European Society for Medical Oncology (ESMO) Congress (ESMO 2024), which will be held for four days from September 13th.
Korean pharmaceutical and biotech industry will unveil their positive clinical trial results at the world's largest cancer conference. The clinical outcomes of various new drug candidates from the South Korea-based pharmaceutical and biotech companies will be presented at the European Society for Medical Oncology (ESMO) Congress (ESMO 2024), which will be held for four days from September 13th. ESMO is one of the three renowned cancer associations, next to the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO).
Rivoceranib demonstrated effectiveness in various solid cancers
▲HLB group will unveil research outcomes for its targeted therapy Rivoceranib for various cancers, including liver cancer, cholangiocarcinoma, esophageal cancer, melanoma, thyroid cancer, and ovarian cancer.
According to industry sources on September 5th,
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)